MY195824A - A Pharmaceutical Composition for Treating Gastrointestinal Diseases - Google Patents

A Pharmaceutical Composition for Treating Gastrointestinal Diseases

Info

Publication number
MY195824A
MY195824A MYPI2017702737A MYPI2017702737A MY195824A MY 195824 A MY195824 A MY 195824A MY PI2017702737 A MYPI2017702737 A MY PI2017702737A MY PI2017702737 A MYPI2017702737 A MY PI2017702737A MY 195824 A MY195824 A MY 195824A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical composition
gastrointestinal diseases
treating gastrointestinal
sucralfate
ranitidine
Prior art date
Application number
MYPI2017702737A
Inventor
Young Ho Jo
Jun Woo Lee
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY195824(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of MY195824A publication Critical patent/MY195824A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a pharmaceutical composition for treating gastrointestinal diseases comprising ranitidine, sucralfate and bismuth subcitrate as active ingredients and a preparation method thereof. According to the present invention, when a combination drug of ranitidine, sucralfate and bismuth subcitrate is prepared, it is possible to address a hygroscopicity problem of ranitidine and increase formulation stability and drug bioavailability by controlling particle sizes of sucralfate and bismuth subcitrate.
MYPI2017702737A 2015-01-30 2016-01-28 A Pharmaceutical Composition for Treating Gastrointestinal Diseases MY195824A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30
KR1020150147513A KR101583452B1 (en) 2015-01-30 2015-10-22 A pharmaceutical composition for treating gastrointestinal diseases
PCT/KR2016/000935 WO2016122226A2 (en) 2015-01-30 2016-01-28 A pharmaceutical composition for treating gastrointestinal diseases

Publications (1)

Publication Number Publication Date
MY195824A true MY195824A (en) 2023-02-22

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017702737A MY195824A (en) 2015-01-30 2016-01-28 A Pharmaceutical Composition for Treating Gastrointestinal Diseases

Country Status (19)

Country Link
EP (1) EP3250199A4 (en)
JP (1) JP6419347B2 (en)
KR (2) KR101583452B1 (en)
CN (1) CN107205947B (en)
AR (1) AR105413A1 (en)
CL (1) CL2017001680A1 (en)
CO (1) CO2017006222A2 (en)
EA (1) EA032385B9 (en)
EC (1) ECSP17038599A (en)
GE (2) GEP20196941B (en)
MA (1) MA41432A (en)
MX (1) MX375765B (en)
MY (1) MY195824A (en)
PE (1) PE20171340A1 (en)
PH (1) PH12017550051A1 (en)
SA (1) SA517382016B1 (en)
TW (1) TWI635859B (en)
UA (1) UA116517C2 (en)
WO (1) WO2016122226A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (en) 2017-10-11 2019-09-24 (주)휴럼 Litsenolide used as an active ingredient for gastrointestinal disease, and A composition comprising the same as an active ingredient
WO2019199134A1 (en) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 Pharmaceutical composition comprising lenalidomide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3874917T2 (en) * 1987-03-09 1993-03-04 Procter & Gamble COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF STOMACH.
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
KR970006083B1 (en) * 1992-01-22 1997-04-23 주식회사 대웅제약 A pharmaceutical composition for treating gastrointestinal disorders
ATE213635T1 (en) * 1994-04-26 2002-03-15 Chugai Pharmaceutical Co Ltd METHOD FOR PRODUCING MELT-GRANULATED SUCRALFATE PREPARATION
JPH0879097A (en) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd Portable radio
KR970006083A (en) 1995-07-06 1997-02-19 한승준 Installation structure of wire fixing device of automobile cowl
JP2001513570A (en) * 1997-08-25 2001-09-04 ザ、プロクター、エンド、ギャンブル、カンパニー Combination preparation for treatment of upper gastrointestinal upset
WO2000078307A1 (en) * 1999-06-21 2000-12-28 Daewoong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
JP2006076956A (en) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk Compounding agent for treating/preventing gastritis
KR101617054B1 (en) * 2008-07-01 2016-04-29 라이온 가부시키가이샤 Solid preparation for internal application
KR20110105223A (en) * 2010-03-18 2011-09-26 일양약품주식회사 Oral pharmaceutical compositions for the prevention or treatment of gastrointestinal diseases containing ilaprazole and a mixture of sucralate and bismuth preparations
KR20140072673A (en) * 2012-12-05 2014-06-13 (주)한국파비스제약 Oral tablet for treatment of gastrointestinal disease

Also Published As

Publication number Publication date
JP6419347B2 (en) 2018-11-07
WO2016122226A2 (en) 2016-08-04
EP3250199A4 (en) 2018-08-08
MX2017007567A (en) 2017-10-19
KR20160094268A (en) 2016-08-09
KR101583452B1 (en) 2016-01-11
PE20171340A1 (en) 2017-09-13
ECSP17038599A (en) 2017-09-29
PH12017550051A1 (en) 2018-01-29
CN107205947B (en) 2020-05-22
GEAP201814551A (en) 2018-08-27
KR101583452B9 (en) 2022-05-02
TW201639559A (en) 2016-11-16
MA41432A (en) 2017-12-05
EA201791458A1 (en) 2017-11-30
GEP20186941B (en) 2019-01-10
WO2016122226A3 (en) 2016-09-15
SA517382016B1 (en) 2021-03-18
EA032385B1 (en) 2019-05-31
CL2017001680A1 (en) 2018-01-12
CN107205947A (en) 2017-09-26
JP2018503672A (en) 2018-02-08
BR112017013857A2 (en) 2018-02-27
AR105413A1 (en) 2017-10-04
CO2017006222A2 (en) 2017-09-20
TWI635859B (en) 2018-09-21
MX375765B (en) 2025-03-07
UA116517C2 (en) 2018-03-26
EA032385B9 (en) 2019-07-31
EP3250199A2 (en) 2017-12-06
GEP20196941B (en) 2019-01-10

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
PH12020550341A1 (en) Niraparib formulations
MX2015013396A (en) Quinolines derivatives as novel anticancer agents.
ZA201707096B (en) Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
EP3093023A4 (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
IL261196A (en) Pharmaceutical composition for treatment of cancer, containing polyphenol compound as active ingredient
WO2015001541A3 (en) Pharmaceutical film composition
EP3279210A4 (en) Peptide having anticancer activity, and pharmaceutical composition and dietary supplement composition for preventing and treating cancer, both of which contain same as active ingredient
PT3604304T (en) Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases
EP3138834A4 (en) Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
EP3909597A4 (en) Pharmaceutical composition for preventing or treating cancer, containing oligopeptide as active ingredient
EP3795170A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING CCN5 USED AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF RETINAL DISEASE
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
PH12017550051A1 (en) A pharmaceutical composition for treating gastrointestinal diseases
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
PH12019500024A1 (en) Pharmaceutical compositions
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
SG11201801423PA (en) Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof
HK1233927A1 (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
HK40005616A (en) Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them